Profound Reports Q2 2026 Financial Results And Q3 Revenue Boosts

Profound Medical reported Q2 2026 financial results where operating expenses declined 16% and net loss improved 39%, alongside a correction noting $2.5M in Q3 revenue due to changed shipment timing. The company reiterated full-year 2026 revenue guidance of $25 million noted an expansion of payer coverage.